|
|
Volumn 534, Issue 7607, 2016, Pages 305-306
|
|
Promising gene therapies pose million-dollar conundrum
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EVOLOCUMAB;
IVACAFTOR;
NEW DRUG;
SOFOSBUVIR;
AMINOPHENOL DERIVATIVE;
MONOCLONAL ANTIBODY;
QUINOLONE DERIVATIVE;
ADRENOLEUKODYSTROPHY;
CALIFORNIA;
CYSTIC FIBROSIS;
DEGENERATIVE DISEASE;
DRUG COST;
GENE THERAPY;
HEALTH CARE FINANCING;
HEMOPHILIA B;
HUMAN;
IMMUNE SYSTEM;
INCOME;
NOTE;
PRIORITY JOURNAL;
SICKLE CELL ANEMIA;
ANEMIA, SICKLE CELL;
BIOTECHNOLOGY;
DRUG INDUSTRY;
ECONOMICS;
GENETICS;
HEALTH INSURANCE;
IMMUNOLOGY;
NEOPLASMS;
TRENDS;
UTILIZATION;
AMINOPHENOLS;
ANEMIA, SICKLE CELL;
ANTIBODIES, MONOCLONAL;
BIOTECHNOLOGY;
CYSTIC FIBROSIS;
DRUG COSTS;
DRUG INDUSTRY;
GENETIC THERAPY;
HUMANS;
INSURANCE, HEALTH;
NEOPLASMS;
QUINOLONES;
SOFOSBUVIR;
|
|
EID: 84975883819
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/534305a Document Type: Note |
|
Times cited : (14)
|
|
References (0)
|
